Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Merav who wrote (750)	5/6/1998 9:43:00 PM
From: yosi s	Respond to of 1491

WOW WOW entremed is a great short. Please temper enthusiasm. On one hand no one was buying PARS when they had a letter of aproval, before resolving some minor issues with FDA. and few believed that this stock would go to 3.5$s upon final FDA. Now you want PARS to be 60$ because they have tamoxiphen. Well. I believe that tamoxiphene will make it but PARS is not doing any human studies on it yet. Recent cancer prevention and entremed story will PARS fast tract tamoxiphen; financing for study may be easier. As for valuation, it is too early. To quote Dr. Jerome Groopman MD, one of the early people at NHI with the HIV story and a great researcher. "IT IS TOO EARLY WAIT FOR HUMAN STUDIES". otherwise too high expectation, stock goes up than sinks, and no one want it again, for a long time. HU 211 is much more relevent and good 1-2 yrs ahead of tamoxiphen. and no one gives it much value. The only good the Entremed story is that it brings the sector back to life and people will look into biotech again. About tamoxiphen the mechanism of action may be similar, as pointed out in the globe article. , but a lot of work needs to be done. Tamoxiphen will be easier to study, and lets hope that PARS will manage to get it in their budget on faster tract. I for one can support more money raising to speed research on this tract as it is hot.